Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

ommon stock.  $25.0 million in gross proceeds were raised, before deducting underwriting discounts and commissions and other offering expenses.  Proceeds from the offering are to support the Phase IIb study of ANA598, as well as for general corporate purposes, including working capital.  Concurrent with the announcement of the offering, Anadys announced its plans to resume clinical investigation of ANA773. Anadys continues to work with Lazard Frères & Co. llc. to explore potential strategic transactions, in parallel with moving the ANA598 and ANA773 programs forward.


  • Receipt of Federal Grant.  In late October, Anadys received notification of a grant of approximately $0.5 million from the U.S. Government for the ANA598 and ANA773 programs under the Qualifying Therapeutic Discovery Project program.  The proceeds from the grant are planned to be used for clinical trial related expenses for the ANA598 and ANA773 programs.Conference Call Webcast Anadys will host a conference call and webcast at 5:00 pm Eastern Standard Time today to discuss its third quarter 2010 financial results and highlights.  A live webcast of the call will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 26363504.  The webcast and telephone replay will be available through November 22, 2010.

    About Anadys Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is p
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
    (Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
    (Date:9/19/2014)... LOS ANGELES , Sept. 19, 2014  CytRx ... and development company specializing in oncology, today announced that ... will present at BioCentury,s 2014 NewsMakers in the Biotech ... p.m. Eastern Time. The conference will take place at ... City . A live and archived ...
    Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
    ... as Chief Strategic Officer -- SHENZHEN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
    ... Dyadic International, Inc. ("Dyadic") (Pink Sheets: ... on the discovery, development, manufacture and sale of ... industrial enzyme and biopharmaceutical industries, today announced that ... complete its previously announced private placement of convertible ...
    Cached Medicine Technology:Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 2Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 3Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 4Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 5Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 6Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer 7Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering 2
    (Date:9/20/2014)... SATURDAY, Sept. 20, 2014 (HealthDay News) -- As flu ... avoid infection is to get a flu shot and ... A primary care doctor can vaccinate people against ... issues patients may have. Retail stores may provide flu ... medical advice, said Dr. Jorge Parada, medical director of ...
    (Date:9/20/2014)... New PharmaPoint Drug Evaluation report, ... 2023?. The asthma market saw very slow growth ... saturated with relatively efficacious standard therapies, such as ... and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and ... the launch of seven novel targeted biologic agents ...
    (Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
    (Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
    (Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
    Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5
    ... in Maryland, USA, has launched a major initiative against the ... all mothers who deliver their babies at the Centre to ... ,Shaking a baby too hard could result in ... ,Nearly 70 percent of shaken baby syndrome cases ...
    ... prevent bites and therefore don’t prevent disease transmission, according ... be manufactured, advertised or used for mosquito bite and ... lead author A. Ali Enayati, Ph.D., lecturer in medical ... Sari, Iran. ,The review appears in the ...
    ... surgical robot developed by the University of Washington, leaves for ... in NASA's mission to submerge a surgeon and robotic gear ... system will be put through its paces in an underwater ... in Seattle will guide its movements. ,The 12th ...
    ... The World Health Organization (WHO) Thursday expressed alarm over ... motorcycles in Asia//, warning that the situation has become ... that young motorcyclists make up a significant percentage of ... countries, such as Cambodia and Malaysia. ,"Factors ...
    ... benefits of a key ingredient in Cannabis, which may help ... that cannabis could help fight brain, prostate and skin cancers. ... growth by 50%, during studies conducted on mice, suggesting that ... the study, the researchers observed that THC was able to ...
    ... health workers should focus their efforts on strengthening HIV/AIDS ... not overcome the pandemic, Kevin De Cock, director of ... deputy director of UNAIDS, said on Tuesday during a ... comments follow the release of a report on Tuesday ...
    Cached Medicine News:Health News:Counseling to Mothers Against too Much Shaking of Children 2Health News:Electronic Mosquito Repellents Fail to Prevent Malaria Transmission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 3Health News:U.N. Officials Call on Countries To Strengthen HIV/AIDS Prevention Efforts 2
    ... InstaCheck® multi-drug test device provides ... easily. Negative results can be ... 3 minutes; positive results require ... one-time urine sample application will ...
    ... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
    ... QuickScreen™ At Home Drug Test is the first ... for home use. The kit includes a rapid ... read instructions, a handbook with frequently asked questions ... sample to the laboratory if the screening device ...
    ... popular onsite test! QuickScreen™ multi-panel dip cards ... and your choice of any conceivable combination ... total flexibility for your drug testing program. ... and the built-in timer tells you when ...
    Medicine Products: